EnfiniT Platform Integrates Novel Target Identification, Precise and Potent T Cell Engineering and Best-in-Class Manufacturing, Improving the Body’s Ability to Fight Disease
Mnemo’s EnfiniT platform leverages complementarity between a new class of antigen with greater tumor specificity and a range of technologies to significantly improve T cell memory, persistence, sensitivity and activity. The result is dramatic improvement in the body’s ability to identify, fight and overcome disease.Learn more about Mnemo’s advances through our scientific publications
The E-antigen platform. E-antigens are splice variants between conventional exons and transposable elements (TE). They represent a new family of cell membrane and intracellular tumor targets that are shared across patients and indications. Intracellular proteins that are unstable or misfolded can be degraded and E-antigen-derived peptides presented on MHC-I. These novel epitopes are immunogenic in humans, are tumor-specific and can be targeted with various approaches including adoptive T cell therapy.
Knockout of SUV39H1. Disruption of the SUV39H1 histone methyltransferase leads to an enhanced T cell memory phenotype and persistence in vivo due to lack of repression of stemness and memory-associated genes. The knockout can be used in the context of adoptive T cell therapy and lead to long-term enhancement of CAR T cell activity resulting in increased survival in preclinical models.
TRAC locus editing. The TCR Alpha Constant chain (TRAC) locus can be targeted to integrate the HIT, TCR or CAR constructs such as 1XX. It positions the constructs under the control of the endogenous TRAC promoter, leading to homogeneous and predictable expression. Expression offered by the TRAC locus also improves the therapeutic activity and results in knockout of the endogenous TCR which is ideal for allogeneic designs. The TRAC locus is adaptable to every editing platform.
HLA-independent TCR (HIT). The HIT design combines elements of the TCR with variable regions from CARs (scFvs) and engages the endogenous CD3 chains in a physiological activation. The HIT structure and sensitivity closely mimics that of the natural TCR, allowing for targeting of cells expressing very low levels of antigen. It is a robust design that can be targeted at the TRAC locus, which by inactivating the endogenous TCR chains prevents mispairing and competition for the CD3 chains.
1XX chimeric antigen receptor (CAR). The 1XX CAR contains a CD28 co-stimulatory domain and mutations in the intracellular ITAM domains of CD3𝛇. The 1XX design results in a T cell memory-like phenotype which leads to enhanced in vivo persistence, tumor control and survival.
Best in Class Manufacturing – Mnemo’s manufacturing expertise is built on the Memorial Sloan Kettering platform, where research leaders pioneered autologous and allogeneic cell products, with unmatched capabilities to deliver high quality products and scalable production processes.
Mnemo’s development plan is driven by the EnfiniT platform as we build and validate our technologies in both solid tumors and blood cancers, as well as preparing the first E-antigen targets.